LONGBOARD HAS BEEN ACQUIRED BY LUNDBECK
On December 2, 2024, H. Lundbeck A/S announced the successful completion of the previously announced transaction to acquire all of the outstanding shares of Longboard Pharmaceuticals, Inc. With the completion of the acquisition, Longboard is now a wholly owned subsidiary of Lundbeck.
To learn more about Lundbeck and the transaction, please visit the Lundbeck website.
The Next Wave of Neurological Medicines is Here.
We are committed to transforming the lives of patients with neurological and rare diseases.
We’re Changing the Game.
We are developing a pipeline of potentially best-in-class neurological assets discovered and optimized by a world-class G protein-coupled receptors (GPCRs) research team at Arena Pharmaceuticals. Many important categories of drugs target GPCRs, which are proteins that regulate numerous aspects of human physiology. Longboard is leveraging 20 years of research to develop the next generation of GPCR-targeted medicines.